CYTOKINETICS, INCORPORATED Realized Investment Gains (Losses)
CYTOKINETICS, INCORPORATED (CYTK) reported Realized Investment Gains (Losses) of $121.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:RealizedInvestmentGainsLosses · last filed 2026-08-06
- CYTOKINETICS, INCORPORATED realized investment gains (losses) for the quarter ending 2026-06-30 was $60.00K, a 275.00% increase year-over-year.
- CYTOKINETICS, INCORPORATED realized investment gains (losses) for the quarter ending 2026-03-31 was $61.00K.
- CYTOKINETICS, INCORPORATED realized investment gains (losses) for the quarter ending 2025-12-31 was $8.00K, a 57.89% decline year-over-year.
- CYTOKINETICS, INCORPORATED realized investment gains (losses) for the quarter ending 2025-09-30 was $1.00K.
- CYTOKINETICS, INCORPORATED realized investment gains (losses) for fiscal 2025 was $25.00K, a 31.58% increase from fiscal 2024.
- CYTOKINETICS, INCORPORATED realized investment gains (losses) for fiscal 2024 was $19.00K.
- CYTOKINETICS, INCORPORATED realized investment gains (losses) for fiscal 2023 was -$35.00K.
- CYTOKINETICS, INCORPORATED realized investment gains (losses) for fiscal 2022 was -$107.00K.
| Period end | Realized Investment Gains (Losses) 3 month | Realized Investment Gains (Losses) 6 month | Realized Investment Gains (Losses) 9 month | Realized Investment Gains (Losses) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $60.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $121.00K 10-Q · filed 2026-08-06 | $129.00K derived: sum of 3 quarters · filed 2026-08-06 | $130.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $61.00K 10-Q · filed 2026-05-05 | $69.00K derived: sum of 2 quarters · filed 2026-05-05 | $70.00K derived: sum of 3 quarters · filed 2026-05-05 | $86.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $9.00K derived: sum of 2 quarters · filed 2026-02-26 | $25.00K derived: sum of 3 quarters · filed 2026-08-06 | $25.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $17.00K derived: sum of 2 quarters · filed 2026-08-06 | $17.00K 10-Q · filed 2025-11-05 | $36.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $16.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $16.00K 10-Q · filed 2026-08-06 | $35.00K derived: sum of 3 quarters · filed 2026-08-06 | $35.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-05 | $19.00K derived: sum of 2 quarters · filed 2026-05-05 | $19.00K derived: sum of 3 quarters · filed 2026-05-05 | |
| 2024-12-31 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $19.00K derived: sum of 2 quarters · filed 2026-02-26 | $19.00K 10-K · filed 2026-02-26 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | |||
| 2023-12-31 | -$35.00K 10-K · filed 2026-02-26 | |||
| 2022-12-31 | -$107.00K 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |